Clinical trials: Hepatitis C, completed
Hepatitis C, Chronic
A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection
A total of 100 people with chronic HCV and recent injection drug use or recipients of opioid substitution therapy will be enrolled in 5 countries and 21 study sites.
- Trial name
- D3FEAT (NCT02498015)
- Testing
- "3D" regimen, "3D" regimen with ribavirin
- Where
- Australia
- Volunteers
- 87 people
- Sponsor
- Kirby Institute
Hepatitis C, Chronic, Opioid-Related Disorders
Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients
The primary objective of study will be to evaluate the effectiveness of interferon-free direct acting antivirals (IFN-free DAAs) in the treatment of chronic hepatitis C virus (HCV) among patients in opioid-substitution treatment…
- Trial name
- INFO (NCT02969668)
- Where
- 18 sites in Germany
- Volunteers
- 326 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hepatitis B, Hepatitis c
Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections
Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections (RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the uptake for screening, linkage to care and treatment…
- Conditions
- Hepatitis B, Hepatitis c, Human Immunodeficiency Virus
- Trial name
- RUNtoBBV (NCT04363411)
- Testing
- finger prick screening for BBV infections and questionnaires by outreaching methodology
- Where
- 10 sites in Belgium
- Volunteers
- 425 people
- Sponsor
- Hasselt University
HCV Coinfection
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus…
- Trial name
- NCT03549832
- Testing
- Sofosbuvir, Simeprevir, Daclatasvir
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Chronic Hepatitis C
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
The primary objectives of this study are to evaluate safety, efficacy, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in adults on dialysis for end stage renal disease (ESRD) with chronic…
- Trial name
- SOF/VEL ESRD (NCT03036852)
- Testing
- SOF/VEL
- Where
- 22 sites in Australia, Canada and 4 more
- Volunteers
- 59 people
- Sponsor
- Gilead Sciences
Hepatitis C
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
The main purpose of this study is to determine the safety and tolerability of multiple dosing of miravirsen in subjects infected with chronic hepatitis C.
- Trial name
- NCT01200420
- Testing
- miravirsen, saline
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00040027
- Testing
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C, Genotype 1
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
The purpose of this study is to evaluate the impact of a physician directed education program on treatment compliance of hepatitis C patients administered triple drug therapy of pegylated interferon, ribavirin and boceprevir.
- Trial name
- OPTIMAL (NCT01405027)
- Testing
- Educational Intervention, Patient education and management skills training
- Where
- 43 sites in United States
- Volunteers
- 197 people
- Sponsor
- Chronic Liver Disease Foundation
Hepatitis C
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therapy (RGT) model.
- Trial name
- NCT03603327
- Testing
- Direct acting anti-viral agents
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Soroka University Medical Center
Hepatitis C, Thalassemia
Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)
Hepatitis C is one of the most common causes of long-term liver disease in the United States. Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C infection.
- Trial name
- HepC (NCT00502788)
- Testing
- Peginterferon Alfa-2a and Ribavirin, Ribavirin
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Carelon Research
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
This was a multicenter study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with ribavirin (RBV) for 12 weeks in treatment naïve and pegylated-interferon alfa-2a or alfa-2b…
- Trial name
- Turquoise-IV (NCT02216422)
- Testing
- Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Ribavirin (RBV)
- Volunteers
- 36 people
- Sponsor
- AbbVie
Cardiovascular Diseases, Hepatitis C
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls.
- Conditions
- Cardiovascular Diseases, Hepatitis C, Hiv
- Trial name
- CHROME (NCT03823911)
- Testing
- Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
- Where
- 2 sites in United States
- Volunteers
- 87 people
- Sponsor
- University of Maryland, Baltimore
HIV/HCV Co-infection, HIV Infections
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
The aim of this study is to assess the efficacy of lopinavir/r in monotherapy and peg-interferon plus ribavirin for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV.
- Trial name
- PEKARI (NCT00866021)
- Testing
- Lopinavir/ritonavir, Lopinavir/ritonavir with two nucleoside analogs
- Where
- 10 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion SEIMC-GESIDA
Chronic Hepatitis C
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both…
- Trial name
- NCT00446134
- Testing
- Taribavirin, Ribavirin
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Liver Fibrosis, Liver Cirrhosis
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis
This study investigated the effectiveness and safety of oltipraz therapy in treating patients with cirrhosis induced by chronic hepatitis type B or C.
- Trial name
- NCT00956098
- Testing
- oltipraz
- Where
- 2 sites in South Korea
- Volunteers
- 81 people
- Sponsor
- HK inno.N Corporation
Chronic Hepatitis C, Hemophilia
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.
- Trial name
- HCV/Hemophil (NCT01704521)
- Testing
- PegInterferon, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Kenneth Sherman
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
This study was designed to assess the safety and efficacy of multiple interferon-free treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone and in combination, with and without ribavirin…
- Trial name
- QUANTUM (NCT01435044)
- Testing
- Sofosbuvir, GS-0938, RBV
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 239 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug…
- Trial name
- NCT00120835
- Testing
- valopicitabine, pegylated interferon
- Where
- 3 sites in United States, Puerto Rico
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.